HPM Partners »

Entrada Therapeutics shares owned by HPM Partners

Quarter-by-quarter ownership of Entrada Therapeutics (TRDA) shares owned by HPM Partners from 13F filings

Historical chart of HPM Partners investment in Entrada Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Entrada Therapeutics held by HPM Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Entrada Therapeutics by HPM Partners

Quarter filed Position value Share count Share price at filing
2026-06-30 $99k 14k 7.36

More positions owned by HPM Partners

Vanguard Index Fds S&p 500 Etf Shs (VOO)
Apple (AAPL)
NVIDIA Corporation (NVDA)
Ishares Tr Core S&p500 Etf (IVV)
State Str Spdr S&p 500 Etf T Tr Unit (SPY)
Microsoft Corporation (MSFT)
Vanguard Tax-managed Fds Van Ftse Dev Mkt (VEA)
Alphabet Cap Stk Cl A (GOOGL)
Alphabet Cap Stk Cl C (GOOG)
Amazon (AMZN)
Broadcom (AVGO)
Ishares Tr Core Msci Eafe (IEFA)
Ishares Tr Core Us Aggbd Et (AGG)
Procter & Gamble Company (PG)
Eli Lilly & Co. (LLY)

View all positions for HPM Partners

Top funds holding Entrada Therapeutics

Baker Bros. Advisors
5AM Venture Management
BlackRock
Merck & Co
Vanguard Capital Management
MPM Oncology Impact Management
TCG Crossover Management
Wellington Management Company
Millennium Management
StepStone
Geode Capital Management
AQR Capital Management
State Street Corporation
T. Rowe Price Associates
Jpmorgan Chase & Co

View all funds holding Entrada Therapeutics